{
  "_metadata": {
    "version": "2.0",
    "type": "targets_index",
    "last_updated": "2026-02-10",
    "total_targets": 14
  },
  "targets": [
    {
      "slug": "TL1A",
      "name": "TL1A",
      "full_name": "TNF-like ligand 1A",
      "category": "immunology",
      "market_status": "race_to_first",
      "total_assets": 8,
      "phase_3_assets": 3,
      "total_committed": 18550,
      "lead_companies": ["Merck", "Roche", "Sanofi/Teva"],
      "hot_target": true,
      "description": "Hot IBD target with anti-fibrotic potential",
      "legacy_slug": "tl1a-ibd",
      "has_full_page": true
    },
    {
      "slug": "B7-H3",
      "name": "B7-H3",
      "full_name": "B7 homolog 3 protein (CD276)",
      "category": "oncology",
      "market_status": "race_to_first",
      "total_assets": 23,
      "phase_3_assets": 2,
      "total_committed": 5755,
      "lead_companies": ["Merck/Daiichi", "GSK/Hansoh", "MacroGenics"],
      "hot_target": true,
      "description": "Highly expressed in solid tumors with limited normal tissue",
      "legacy_slug": "b7h3-adc",
      "has_full_page": true
    },
    {
      "slug": "GLP-1",
      "name": "GLP-1",
      "full_name": "Glucagon-like peptide-1 receptor",
      "category": "metabolic",
      "market_status": "approved",
      "total_assets": 25,
      "phase_3_assets": 9,
      "approved_assets": 4,
      "total_committed": 9450,
      "lead_companies": ["Novo Nordisk", "Eli Lilly", "Amgen"],
      "hot_target": true,
      "description": "$50B+ market. Oral formulation key.",
      "legacy_slug": "glp1-obesity",
      "has_full_page": true
    },
    {
      "slug": "KRAS",
      "name": "KRAS G12C",
      "full_name": "Kirsten rat sarcoma viral oncogene",
      "category": "oncology",
      "market_status": "approved",
      "total_assets": 7,
      "phase_3_assets": 1,
      "approved_assets": 2,
      "lead_companies": ["Amgen", "Mirati/BMS", "Revolution Medicines"],
      "description": "From undruggable to approved. G12D next frontier.",
      "legacy_slug": "kras",
      "has_full_page": true
    },
    {
      "slug": "Cell-Therapy",
      "name": "Cell Therapy",
      "full_name": "In Vivo CAR-T / Cell Therapy Evolution",
      "category": "modality",
      "market_status": "emerging",
      "total_assets": 8,
      "lead_companies": ["Eli Lilly/Orna", "AbbVie/Capstan", "AstraZeneca/EsoBiotec"],
      "hot_target": true,
      "description": "$7B+ in vivo M&A wave. Ex vivo economics broken for autoimmune.",
      "legacy_slug": "cell-therapy",
      "has_full_page": true
    },
    {
      "slug": "STAT6",
      "name": "STAT6",
      "full_name": "Signal Transducer and Activator of Transcription 6",
      "category": "immunology",
      "market_status": "race_to_first",
      "total_assets": 6,
      "phase_3_assets": 0,
      "total_committed": 3830,
      "lead_companies": ["Kymera Therapeutics", "Sanofi/Nurix", "Gilead/LEO"],
      "hot_target": true,
      "description": "Undruggable no more. Oral PROTAC matches dupilumab.",
      "legacy_slug": "stat6",
      "has_full_page": true
    },
    {
      "slug": "miR-124",
      "name": "miR-124",
      "full_name": "MicroRNA-124 (miR-124)",
      "category": "immunology",
      "market_status": "race_to_first",
      "total_assets": 2,
      "phase_3_assets": 1,
      "lead_companies": ["Abivax", "Formation Bio/Kenmare"],
      "hot_target": true,
      "description": "MicroRNA that resets immune balance. Obefazimod Phase 3 positive in UC.",
      "legacy_slug": "mir-124",
      "has_full_page": true
    },
    {
      "slug": "FcRn",
      "name": "FcRn",
      "full_name": "Neonatal Fc Receptor",
      "category": "immunology",
      "badge": "Approved Drug Exists",
      "market_leader": "VYVGART (efgartigimod)",
      "challenger": "IMVT-1402 (Immunovant)",
      "companies_pursuing": 6,
      "tagline": "IgG recycling blocker for autoimmune; argenx $4B+ franchise",
      "has_full_page": false
    },
    {
      "slug": "KIT",
      "name": "KIT",
      "full_name": "KIT Proto-Oncogene",
      "category": "immunology",
      "badge": "Race to First",
      "frontrunner": "Barzolvolimab (Celldex)",
      "fast_follower": "TBD",
      "companies_pursuing": 3,
      "tagline": "Mast cell depletion for chronic urticaria and prurigo nodularis",
      "has_full_page": false
    },
    {
      "slug": "il18",
      "name": "IL-18",
      "full_name": "Interleukin-18",
      "category": "immunology",
      "badge": "Race to First",
      "frontrunner": "EVO301 (Evommune)",
      "fast_follower": "Tadekinig alfa (AB2 Bio)",
      "companies_pursuing": 3,
      "tagline": "IL-18 neutralization for AD — Phase 2a hit primary endpoint today (Feb 10). Stock +50%.",
      "has_full_page": false
    },
    {
      "slug": "treg",
      "name": "Treg Stimulation",
      "full_name": "Regulatory T-Cell Stimulation",
      "category": "immunology",
      "badge": "Race to First",
      "frontrunner": "Rezpegaldesleukin (Nektar)",
      "fast_follower": "TBD",
      "companies_pursuing": 3,
      "tagline": "First-in-class Treg biologic — Phase 2b maintenance showed 83% EASI-75 at week 52. Phase 3 planned.",
      "has_full_page": false
    },
    {
      "slug": "menin-mll",
      "name": "Menin-MLL",
      "full_name": "Menin-MLL Interaction Inhibitors",
      "category": "oncology",
      "badge": "Approved Drug Exists",
      "market_leader": "Revuforj (revumenib, Syndax)",
      "challenger": "Ziftomenib (Kura Oncology)",
      "companies_pursuing": 4,
      "tagline": "First-in-class for KMT2A-rearranged AML",
      "has_full_page": false
    },
    {
      "slug": "tigit",
      "name": "TIGIT",
      "full_name": "T-cell immunoreceptor with Ig and ITIM domains",
      "category": "oncology",
      "badge": "Race to First",
      "frontrunner": "Domvanalimab (Arcus/Gilead)",
      "fast_follower": "Ociperlimab (BeiGene)",
      "companies_pursuing": 5,
      "tagline": "Immune checkpoint — Fc-silent design may crack the code",
      "has_full_page": false
    },
    {
      "slug": "dmd",
      "name": "DMD Gene Therapy",
      "full_name": "Duchenne Muscular Dystrophy Gene Therapy",
      "category": "rare_disease",
      "badge": "Approved Drug Exists",
      "market_leader": "Elevidys (Sarepta)",
      "challenger": "Exon-skipping therapies (Sarepta)",
      "companies_pursuing": 3,
      "tagline": "First gene therapy for Duchenne muscular dystrophy",
      "has_full_page": false
    }
  ],
  "categories": {
    "oncology": {
      "name": "Oncology",
      "color": "#dc2626",
      "count": 4
    },
    "immunology": {
      "name": "I&I",
      "color": "#7c3aed",
      "count": 6
    },
    "metabolic": {
      "name": "Metabolic",
      "color": "#059669",
      "count": 1
    },
    "modality": {
      "name": "Modality",
      "color": "#9333ea",
      "count": 1
    },
    "rare_disease": {
      "name": "Rare Disease",
      "color": "#d97706",
      "count": 1
    }
  }
}
